Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial

The Lancet(2025)10.1016/s0140-6736(25)01720-9Source: DataRank Database

Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial is a research paper published in The Lancet (2025). On theSindex it has a DataRank of 0.590. It has been cited 50 times.

N/A

0.590DataRank · unranked

Scored on demand from live citation data

50 citations

Free full text

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 31.34)OA: closedTopics (48)IDs (PubMed, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.590

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (27)

Jia Fan ORCID,Shaolai Zhou,Yunfan Sun,Fei Liang,Yuan Ji ORCID

Live enrichment

PubMed:41125112 OpenAlex:https://openalex.org/W4415331968

Shanghai Hospital Development Center

Grant: SHDC2020CR1022B

National Natural Science Foundation of China

Grant: 82488101

Jiangsu Hengrui Medicine

Science and Technology Commission of Shanghai Municipality

FWCI

31.34

Citation Percentile

1.0%

Citation Trend

2025

2026

closedLicense: https://doi.org/10.15223/policy-004

publisherhttps://api.elsevier.com/content/article/PII:S0140673625017209?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0140673625017209?httpAccept=text/plain

journalhttps://doi.org/10.1016/s0140-6736(25)01720-9

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41125112

Fields of Study

Hepatocellular Carcinoma Treatment and PrognosisCancer, Stress, Anesthesia, and Immune ResponseCancer Immunotherapy and BiomarkersAdultAgedFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularChemotherapy, AdjuvantChinaHepatectomyLiver NeoplasmsNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingAntineoplastic AgentsProtein Kinase InhibitorsPyridines

MeSH Terms

AdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChinaFemaleHepatectomyCarcinoma, HepatocellularHumansLiver NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPyridinesChemotherapy, AdjuvantNeoadjuvant TherapyProtein Kinase InhibitorsAntibodies, Monoclonal, Humanized

Keywords

PerioperativeHepatocellular carcinomaOverall survivalRandomized controlled trialClinical trialResectionCarcinoma